183723-09-3

Basic information

• Product Name: 3-bromo-4-methylbenzamide
• Synonyms: 3-bromo-4-methylbenzamide;3-bromo-4-methylbenzamide(SALTDATA: FREE)
• CAS NO: 183723-09-3
• Molecular Formula: C₈H₈BrNO
• Molecular Weight: 214.06
• Product Categories: Anilines, Amides & Amines;Bromine Compounds
• Mol File: 183723-09-3.mol

Chemical Properties

• Boiling Point: 284.9°C at 760 mmHg
• Flash Point: 126.1°C
• Appearance: /
• Density: 1.522g/cm³
• Vapor Pressure: 0.00289mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.59±0.50(Predicted)
• CAS DataBase Reference: 3-bromo-4-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-4-methylbenzamide(183723-09-3)
• EPA Substance Registry System: 3-bromo-4-methylbenzamide(183723-09-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 183723-09-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
3-bromo-4-methylbenzamide is used as a building block for the synthesis of more complex molecules, leveraging its reactive bromine and methyl groups to form a variety of organic compounds.
Used in Chemical Reactions:
It serves as a reagent in various chemical reactions, facilitating the formation of new bonds and the transformation of other molecules, thanks to its amide functionality and the presence of a bromine atom.
Used in Pharmaceutical Production:
3-bromo-4-methylbenzamide is utilized as a starting material in the production of pharmaceuticals, where its specific structural features can be exploited to develop new drugs with potential therapeutic applications.
Used in Agrochemical Production:
Similarly, in the agrochemical industry, 3-bromo-4-methylbenzamide is used as a starting material for the development of new agrochemicals, such as pesticides and herbicides, due to its potential to be incorporated into molecules with bioactive properties.

InChI:InChI=1/C8H8BrNO/c1-5-2-3-6(8(10)11)4-7(5)9/h2-4H,1H3,(H2,10,11)

Upstream product

• 42872-74-2 3-bromo-4-methyl-benzonitrile 
• 7697-26-9 3-bromo-4-methylbenzoic acid 
• 21900-33-4 3-bromo-4-methylbenzoyl chloride 
• 79-37-8 oxalyl dichloride 
• 68120-35-4 (3-bromo-4-methyl-phenyl)-methanol 
• 60208-05-1 2-bromo-1-(3-bromo-4-methylphenyl)ethan-1-one 
• 167960-11-4 3-bromo-4-methylstyrene 

Downstream Products

• 903522-17-8 3-Bromo-4-methyl-thiobenzamide 
• 42872-74-2 3-bromo-4-methyl-benzonitrile 
• 882679-88-1 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1177558-32-5 (3-bromo-4-methylphenyl)methanamine 
• 1195621-94-3 1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbaldehyde 
• 947162-60-9 1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborole-6-carbonitrile 
• 201342-56-5 (2-bromo-4-cyanophenyl)methyl acetate 
• 903522-18-9 2-(3-bromo-4-methylphenyl)thiazole 
• 1211578-89-0 2-(3-bromo-4-methyl-phenyl)-oxazole 

Relevant articles and documents

2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein α, β, R2, R3, R4, R5, R8, R9, X1, X6, and X7 are defined in the specification. The compounds of formula 1 are receptor-interacting protein kinase 2 (RIPK2) inhibitors for treating e.g. type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer and non-malignant proliferative disorders, such as e.g. allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjogren's syndrome, ankylosing spondylitis, Behcet's disease, graft versus host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction and thrombosis. The present description discloses the preparation of exemplary compounds as well as pharmacological data thereof (e.g. pages 107 to 208; examples 1 to 109; table 1). An exemplary compound is e.g. N-cyclopropyl-2-fluoro-5-(l-(2-fluoroethyl)-3-(l-hydroxy-2-methylpropan-2-yl)-2-oxo-2,3-dihydro-lH-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide (example 1).

Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870

The aromatic substrate profile of the cobalt nitrile hydratase from Rhodococcus rhodochrous ATCC BAA 870 was evaluated against a wide range of nitrile containing compounds (>60). To determine the substrate limits of this enzyme, compounds ranging in size from small (90 Da) to large (325 Da) were evaluated. Larger compounds included those with a biaryl axis, prepared by the Suzuki coupling reaction, Morita–Baylis–Hillman adducts, heteroatomlinked diarylpyridines prepared by Buchwald–Hartwig crosscoupling reactions and imidazo[1,2a]pyridines prepared by the Groebke–Blackburn–Bienaymé multicomponent reaction. The enzyme active site was moderately accommodating, accepting almost all of the small aromatic nitriles, the diarylpyridines and most of the biaryl compounds and Morita–Baylis–Hillman products but not the Groebke–Blackburn–Bienaymé products. Nitrile conversion was influenced by steric hindrance around the cyano group, the presence of electron donating groups (e.g., methoxy) on the aromatic ring, and the overall size of the compound.

1,3-Dibromo-5,5-dimethylhydantoin mediated oxidative amidation of terminal alkenes in water

A variety of terminal alkenes were converted to the corresponding amides in yields of 25 to 86% in water via treatment with 1,3-dibromo-5,5-dimethylhydantoin, followed by reaction with molecular iodine and aq. NH3 (or amine) in one pot. This metal- and organic solvent-free protocol is not only suitable for styrene derivatives, but also, for the first time, works well on terminal aliphatic alkenes.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.

AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

BENZOXAZINE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

INDOLE DERIVATIVES AS CRAC MODULATORS

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with calcium release-activated calcium channels (CRAC).

Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents

A series of boron-containing benzoxaborole compounds was designed and synthesized for a structure-activity relationship investigation surrounding 7-(HOOCCH2CH2)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (1) with the goal of discovering